Synonyms K-OR-1, Kappa-type opioid receptor, KOR + [6] |
Introduction G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. |
Mechanism Free radicals inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. South Korea |
First Approval Date24 Apr 2025 |
Target |
Mechanism κ opioid receptor agonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date23 Aug 2021 |
Mechanism κ opioid receptor agonists [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Taiwan Province |
First Approval Date11 Jul 2016 |
Start Date29 Dec 2025 |
Sponsor / Collaborator |
Start Date01 Nov 2025 |
Sponsor / Collaborator [+4] |
Start Date30 Jul 2025 |
Sponsor / Collaborator |